Demand for vitamin and nutritional supplements is surging in India. This trend follows the increased availability of semaglutide-based weig...

Pfizer is prioritizing India for future growth. The company plans to launch new medicines here soon after their global release. Pfizer aims...

Over a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...

A new weight-loss drug, retatrutide, is generating excitement. This investigational medicine targets three hormone receptors, offering a po...

India's obesity drug market is experiencing rapid growth, driven by rising lifestyle diseases and the launch of blockbuster therapies. The ...

Eli Lilly's Mounjaro drug has become India's top seller for October as sales reached one billion rupees. This anti-obesity medication helps...

India is poised to establish itself as a pivotal hub for semaglutide API manufacturing. Leading pharmaceutical firms are amplifying their p...

Mounjaro has made a splash in Indian healthcare, emerging as the go-to solution for both diabetes management and weight loss. This remarkab...

Cipla is set to enter India's weight management market, addressing the increasing demand for obesity solutions, while also strengthening it...

Recent research suggests that Ozempic and other GLP-1 receptor agonists, commonly used for weight loss, may offer unexpected anti-cancer be...

India's anti-obesity drug market has surged, growing over fourfold in five years, reaching Rs 576 crore by March 2025. Semaglutide pill Ryb...

Weight-loss drugs: Biocon Ltd. is shifting focus to anti-obesity therapies as patents for key medications expire, leading to a surge in gen...

Eli Lilly has commenced phase three clinical trials in India for a new oral weight-loss drug called orforglipron. The trials aim to assess ...

Novo Nordisk A/S bought Cardior Pharmaceuticals for $1 billion to enhance cardiovascular treatments. Cardior's microRNA-targeting therapies...

New data suggests that semaglutide may also cut the risk of stroke or heart attack, and may delay the progression of kidney disease in diab...

At around Rs 21,000 crore annually, cardiac medication forms the biggest therapy of drugs being bought by Indians today. A decade ago, it w...

Insulin brand Human Mixtard, oral formulation Glycomet GP, insulin Lantus, oral formulations Galvus Met and Janumet are now in the top-sell...